Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen

W P STROSS, R A WARNKE, D J FLAVELL, S U FLAVELL, D SIMMONS, K C GATTER, D Y MASON

From the Nuffield Departments of Pathology and Surgery, University of Oxford, John Radcliffe Hospital, Oxford, the Department of Pathology, Southampton General Hospital, Southampton, and the Department of Pathology, Stanford University Medical Center, Stanford, California, USA

SUMMARY  Three monoclonal antibodies MT1, L60 (Leu-22), and DF-T1, were reported independently as recognising human T cells in routinely processed, paraffin wax embedded tissue. The present study was performed to compare these three reagents in terms of their immunocytochemical reactions and target molecule(s). On Western blotting of white cell extracts the three antibodies reacted with antigens of the same molecular weight (range 110–160 kilodaltons). Furthermore, their immunocytochemical reactivity with normal human cells, as analysed by two-colour flow cytometry, was essentially identical (labelling of monocytes, most T lymphocytes, and weak reactions with some B cells), and the antibodies gave closely similar reactions on 54 white cell derived neoplasms. To identify the target antigen for these three reagents, antibodies from the Third International Workshop on Leucocyte Antigens were reviewed and it was shown that the Western blotting and immunocytochemical reactions of MT1, L60 (Leu-22), and DF-T1 were identical with those of the reagents which defined the CD43 antigen (also known as leucosialin or sialophorin). Furthermore, all these antibodies reacted with cells transfected with a cDNA clone encoding CD43.

It is concluded that antibodies MT1, L60 (Leu-22), and DF-T1 all recognise the heavily glycosylated myeloid/lymphoid associated CD43 antigen.

There has been much recent interest in monoclonal antibodies which detect fixation resistant antigens and which can be used to distinguish between B and T cell lymphomas in routinely processed paraffin wax sections. One widely used reagent of this sort is MT1 which recognises human T cells and myeloid cells. Antibody L60 (Leu-22) shows some similarities in its reported reaction patterns, and recently a third anti-T cell antibody, DF-T1, has also been reported to work in fixed material (Flavell DJ, Flavell SV, Stross WP, Jones DB, Mason DY, Wright DH, unpublished observations). The molecular targets for these antibodies, however, have not been clearly defined and it is therefore unclear to what extent their reactions are comparable. This is useful information for the pathologist when deciding which antibodies to include in a routine phenotyping panel, or to exclude on the basis that they duplicate other reactions.

This paper shows that MT1, DF-T1, and L60 (Leu-22) recognise the same molecule and that the molecule defined by these antibodies is the CD43 antigen. This molecule (also known as sialophorin, gpL 115, leucosialin and leucocyte sialoglycoprotein) is defective in the Wiskott-Aldrich syndrome and may participate in T cell activation.

Material and methods

DF-T1 was prepared in one of the authors' (DJF) laboratories. MT1 and L60 (Leu-22) were obtained from Euro-Diagnostics and Becton Dickinson, respectively. The CD43 antibodies G10-2, G19-1, and 84-3C1 were from the Third Workshop on Human Leucocyte Differentiation Antigens; other reagents were from Dako or one of the authors' laboratories (table 1).

Antibodies were isolated from ascitic fluid using a protein A sepharose column (Bioprocessing Consett) and conjugated to fluorescein isothiocyanate (FITC)
Table 1  Antibodies used in this study

<table>
<thead>
<tr>
<th>Specificity</th>
<th>Clone</th>
<th>Source</th>
<th>Form used</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD2 (T11)</td>
<td>X53</td>
<td>Author’s laboratory</td>
<td>FITC-conjugate</td>
</tr>
<tr>
<td>CD3 (T3)</td>
<td>T3-4B5</td>
<td>DAKO</td>
<td>Supernate</td>
</tr>
<tr>
<td>CD4 (T4)</td>
<td>T3-10</td>
<td>DAKO</td>
<td>FITC-conjugate</td>
</tr>
<tr>
<td>CD5 (T1)</td>
<td>DK23</td>
<td>DAKO</td>
<td>Supernate</td>
</tr>
<tr>
<td>CD8 (T8)</td>
<td>DK25</td>
<td>DAKO</td>
<td>FITC-conjugate</td>
</tr>
<tr>
<td>CD19 (B4)</td>
<td>HD37</td>
<td>Author’s laboratory</td>
<td>FITC-conjugate</td>
</tr>
<tr>
<td>See text</td>
<td>DF-T1</td>
<td>Author’s laboratory</td>
<td>Supernate/ascitic fluid</td>
</tr>
<tr>
<td>See text</td>
<td>MT1</td>
<td>Euro-Diagnostics</td>
<td>Supernate</td>
</tr>
<tr>
<td>See text</td>
<td>L60 (Leu-22)</td>
<td>Becton Dickinson</td>
<td>Asitic fluid</td>
</tr>
<tr>
<td>CD43</td>
<td>G10-2</td>
<td>Ledbetter</td>
<td>Asitic fluid</td>
</tr>
<tr>
<td>CD43</td>
<td>G19-1</td>
<td>Ledbetter</td>
<td>Asitic fluid</td>
</tr>
<tr>
<td>CD43</td>
<td>84-3C1</td>
<td>Vilella</td>
<td>Asitic fluid</td>
</tr>
</tbody>
</table>

Isomer 1 (Sigma) at a protein concentration of 2 mg/ml, using 140 μg FITC/mg of protein. Antibody DF-T1, at a protein concentration of 2 mg/ml, was conjugated to N-hydroxysuccinimidobiotin (Sigma) dissolved in dimethyl sulphoxide 1 mg/ml (150 μg of biotin/mg antibody).

Tissues and cells

Cell lines

The HL60 promyelocytic cell line and the myeloblastic cell line KG1 were harvested in logarithmic growth phase. COS-7 cells were transfected with vector CDM8 alone, or with vector containing an insert (from a human placental cDNA library) that had been selected by a panning technique using the three CD43 antibodies from the Third Workshop. Cytospins of the transfected cells were fixed in acetone methanol 1:1 for one minute.

Normal tissues

A bone marrow aspirate was obtained from a patient with lymphoma who was in remission. Tonsils were obtained from routine tonsillectomies in the Ear, Nose and Throat Department, Radcliffe Infirmary, Oxford. Brain tissue was obtained at necropsy, and thymus from a child undergoing thoracotomy. Cryostat sections of 6 μm thickness were fixed in acetone and stored, wrapped in foil at -20°C. Paraffin wax embedded sections were prepared using routine methods after fixation in formalin saline.

Lymphomas/leukaemias

Blood smears were obtained from 15 cases of chronic lymphatic leukaemia (CLL).

Paraffin wax embedded sections were obtained from haematolymphoid neoplasms which had been phenotyped with a panel of antibodies in cryostat sections. Cases from the histopathology department of the John Radcliffe Hospital had been fixed in formalin saline; cases from the department of pathology, Stanford University Medical Center had been fixed in 10% neutral buffered formalin.

White cell extracts

Peripheral blood mononuclear cells were obtained from a normal subject by centrifugation over Lymphoprep (Nyegaard). Mononuclear cells were fractionated by centrifugation through Percoll:1 g 1-06 (Pharmacia). Lymphocytes and monocytes were more than 95% pure. Granulocytes were obtained from the resuspended cell pellets by sedimentation of erythrocytes with 4% Dextran 150 (BDH) in phosphate buffered saline (PBS). Cells were washed three times in PBS and 2 × 10^7 cells solubilised in 1 ml of 0-5% Nonidet P40 (BDH) containing 1 mM phenylmethyl-sulphonylfluoride (Sigma) and 20 mM ethylene glyco-bis (amino ethyl ether) N,N,N',N'-tetra acetic acid (Sigma).

IMMUNOCYTOCHEMICAL ANALYSIS BY FLOW CYTOMETRY

Cell suspensions

Unfractionated peripheral blood mononuclear cells and fresh tonsil cells in tissue culture medium (Gibco RPMI 1640) containing 10% fetal calf serum were separated on a density gradient as above. In each experiment negative controls were included: (a) unstained cells; (b) cells incubated with only the secondary antibody or phycoerythrin, or both.

Single labelling

A 50 μl aliquot of cell suspension (5 × 10^6/ml) was mixed with 50 μl primary antibody and incubated on ice for 30 minutes. The cells were washed twice and 50 μl of FITC-conjugated rabbit anti-mouse F(ab')2 diluted 1/20 (Dako) was added. After incubation on ice for 30 minutes the cells were washed twice and fixed in 200 μl of 1-5% formaldehyde in PBS.

Double labelling

Cells were incubated with two primary antibodies (conjugated to biotin or FITC) washed, incubated with streptavidin-phycoerythrin, and processed as above.

Analysis

Flow cytometry was performed with FACScan (Becton Dickinson). The relevant cell population was selected with live gates, and a minimum of 104 cells were analysed.

IMMUNOENZYMATIC LABELLING OF TISSUE SECTIONS AND CELLS

Paraffin wax sections were dewaxed, hydrated, and incubated for 20–30 minutes in 0-1% trypsin solution containing 0-1% calcium chloride (pH 7-8). Tissue sections and cytospin slides were stained using an automated alkaline phosphatase anti-alkaline phosphatase (APAAP) method.
**Antigen detected by MTI, DF-T1, and L60 (Leu-22)**

**Results**

**Western Blotting**

Immunoblotting results obtained with DF-T1, MT1, and L60 (Leu-22) on five different white cell lysates are shown in Fig. 1. The molecular weight heterogeneity of the antigen from different sources can be clearly seen as can the fact that the three antibodies gave identical blotting results. The apparent molecular weights are listed in Table 2.

Western blots obtained with KG1 lysate using DF-T1, MT1, L60 (Leu-22) and the three CD43 antibodies are shown in Fig. 2. All six antibodies clearly identified a major band with an apparent molecular weight of 110 kilodaltons.

**Table 2.** Molecular weights of antigens extracted from different sources identified by DF-T1, MT1, and L60 (Leu-22)

<table>
<thead>
<tr>
<th>Antigen source</th>
<th>Molecular weight (kilodaltons)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HL60 cells</td>
<td>130, 140, 150, 160</td>
</tr>
<tr>
<td>KG1 cells</td>
<td>95, 110, 120</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>115, 130</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>130, 135</td>
</tr>
<tr>
<td>Monocytes</td>
<td>110-150 (smear)</td>
</tr>
</tbody>
</table>

Major bands are emboldened.
Fig 2 Western blotting of DF-T1, MT1, L60 and three CD43 antibodies performed on KG1 lysate showing that the six antibodies recognise molecules of the same molecular weight. Molecular weight standards are shown in the left hand track.

kilodaltons and a minor band at 95 kilodaltons, though the 95 kilodalton band was only weakly detected with antibodies DF-T1, MT1, 84-3C1, G19-1 and G10-2. In this instance L60 (Leu-22) was the only antibody to detect a weak band at 120 kilodaltons.

**FLOW CYTOMETRIC ANALYSIS**

Antibodies MT1, DF-T1, and L60 (Leu-22) and the three known anti-CD43 antibodies gave similar patterns of labelling when peripheral blood mononuclear cells were analysed, all monocytes and most lymphoid cells being positive. Double labelling showed that the DF-T1 positive lymphoid cells were T cells (CD2, CD4, and CD8 positive, and negative with the B cell antigen CD19) (fig 3a).

There was a less clear distinction between positive and negative tonsil cells than had been obtained with blood leucocytes, but the results with the six antibodies were essentially identical. A small proportion (7.6%) of B cells (CD19 positive cells) were stained, and a small proportion (8.9%) of T cells (CD2 positive cells) were negative (fig 3b).

**IMMUNOCYTOCHEMISTRY ON LYMPHOID TISSUE**

**Normal tissues**

Antibodies MT1, DF-T1, and L60 (Leu-22) showed a similar pattern of labelling of interfollicular T zones in tonsils as well as intense staining of scattered cells in the B follicles. None of the antibodies convincingly labelled B cell areas. In paraffin wax embedded lymph node (fig 4) an essentially identical pattern was seen, but reactivity of neutrophils and macrophages with MT1, DF-T1, and L60 (Leu-22) was more easily appreciated.

Thymus sections showed strong labelling of most cells in both the cortex and the medulla, similar to anti-CD3.

Bone marrow smears showed strong labelling of myeloid cells, megakaryocytes, and erythroid precursors with DF-T1, MT1, and L60 (Leu-22) (fig 5). Platelets and red cells were unlabelled, as were occasional cells of lymphoid morphology.

When compared with normal tissues (using paraffin wax sections of tonsil and cryostat sections of tonsil, thymus, and brain) the three anti-CD43 antibodies seemed to be identical with DF-T1.

**Lymphoid neoplasms**

Antibodies MT1, DF-T1, and L60 (Leu-22) showed similar patterns of reactivity on paraffin wax sections from 37 haematolymphoid malignancies. In general, T cell lymphomas showed identical patterns of staining with the three antibodies (table 3, fig 6).

Reactivity of B cell tumours was most commonly

<table>
<thead>
<tr>
<th>Neoplasms</th>
<th>MT1</th>
<th>DF-T1</th>
<th>L60 (Leu-22)</th>
</tr>
</thead>
<tbody>
<tr>
<td>B cell lymphoma/leukaemia*:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small lymphocytic/CLL</td>
<td>4/6</td>
<td>4/6</td>
<td>5/6</td>
</tr>
<tr>
<td>Follicular, all types (centroblastic)</td>
<td>0/6</td>
<td>0/6</td>
<td>2/6</td>
</tr>
<tr>
<td>Diffuse small cleaved cells (centrocytic)</td>
<td>2/2</td>
<td>1/2</td>
<td>2/2</td>
</tr>
<tr>
<td>Diffuse large cell (centroblastic)</td>
<td>0/2</td>
<td>0/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Immunoblastic</td>
<td>0/2</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Hairy cell leukaemia</td>
<td>0/2</td>
<td>0/2</td>
<td>0/2</td>
</tr>
<tr>
<td>Totals</td>
<td>6/20</td>
<td>5/20</td>
<td>11/20</td>
</tr>
<tr>
<td>T cell lymphoma:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphoblastic</td>
<td>2/2</td>
<td>1/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Peripheral</td>
<td>9/13</td>
<td>9/13</td>
<td>10/13</td>
</tr>
<tr>
<td>Totals</td>
<td>11/15</td>
<td>10/15</td>
<td>11/15</td>
</tr>
<tr>
<td>Miscellaneous:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>True histiocytic lymphoma</td>
<td>1/2</td>
<td>1/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Acute myelogenous leukaemia (AML)</td>
<td>2/2</td>
<td>2/2</td>
<td>2/2</td>
</tr>
</tbody>
</table>

*B lymphomas are classified according to the Working Formulation with the Kiel classification in parentheses.
Antigen detected by MT1, DF-T1, and L60 (Leu-22)

Fig 3  (a) Dual colour FACS analysis of peripheral blood lymphocytes with DF-T1 in combination with CD2, CD4, CD8 and CD19 (both axes log fluorescence intensity).
(b) Dual colour FACS analysis of tonsil cell suspension with DF-T1 in combination with CD2 and CD19 (both axes log fluorescence intensity).

seen in diffuse small cell lymphomas/leukaemias (fig 7). A few of these positively labelled B cell tumours showed staining equal to that of the T cell tumours but most were only weakly or focally stained. In the negative B cell cases reactive T cells, macrophages (fig 8), and epithelioid giant cells (fig 9) were stained. Some discrepancies in the reaction patterns of the three antibodies were observed (table 3)—that is, more B lymphomas and leukaemias were stained by L60 (Leu-22) than by MT1 and DF-T1 (11 of 20 cases compared with six and five cases, respectively). The labelling patterns of the antibodies on two histiocytic neoplasms and two cases of acute myeloid leukaemia (AML) were identical (table 3).
Smears
In 11 of 15 cases of B cell CLL strong staining with DF-T1, MT1, and L60 (Leu-22) was seen (fig 10). The remaining four cases were negative for all three antibodies, granulocytes and monocytes providing an internal positive control. There was no correlation between the expression of CD5 (found in 12 of the 15 cases) and reactivity with DF-T1, MT1, and L60 (Leu-22).

Table 4  Previously reported reactions of MT1 and L60 (Leu-22) on paraffin wax embedded white cell neoplasms

<table>
<thead>
<tr>
<th>Authors</th>
<th>B cell derived neoplasms</th>
<th>T cell derived neoplasms</th>
<th>Histiocytic lesions</th>
<th>Myeloid leukaemias</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% positive (No tested)</td>
<td>% positive (No tested)</td>
<td>% positive (No tested)</td>
<td>% positive (No tested)</td>
</tr>
<tr>
<td>MT1:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poppema et al, 1987²</td>
<td>49 (55)</td>
<td>100 (20)</td>
<td>100 (8)</td>
<td>ND</td>
</tr>
<tr>
<td>Ng et al, 1988²</td>
<td>4 (74)</td>
<td>69 (55)</td>
<td>0 (1)</td>
<td>75 (4)</td>
</tr>
<tr>
<td>Norton and Isaacson, 1986, 1987²</td>
<td>22 (64)</td>
<td>83 (24)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Dobson et al, 1987²</td>
<td>42 (33)</td>
<td>89 (27)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Hall et al, 1987²</td>
<td>0 (8)</td>
<td>88 (8)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>West et al, 1986¹</td>
<td>0 (26)</td>
<td>100 (10)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>L60:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Strickler et al, 1987⁴</td>
<td>64 (11)</td>
<td>100 (22)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Ngan et al, 1988³¹</td>
<td>42 (77)</td>
<td>80 (5)</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Said et al, 1989⁶³</td>
<td>37 (67)</td>
<td>90 (60)</td>
<td>ND</td>
<td>0 (6)</td>
</tr>
</tbody>
</table>

ND, no data.
Antigen detected by MT1, DF-T1, and L60 (Leu-22)

Fig 8 Reactive T cells and macrophages in a case of B cell non-Hodgkin's lymphoma stained with DF-T1. Note lack of staining of the tumour cells.
Fig 9 Epithelioid giant cells in a case of B cell non-Hodgkin's lymphoma stained with DF-T1. Note positive reactive T cells and negative tumour cells in this case.
Fig 10 Blood smear from a case of B cell CLL. There is strong staining of all but one of the lymphocytes.
Fig 11 COS-7 cells transfected the CD43 gene, stained with antibody DF-T1, showing the intense labelling of a minority of the cells.

Transfectants
COS-7 cells transfected with the CD43 gene reacted strongly with DF-T1, MT1, and L60 (Leu-22) and also with antibodies known to recognise CD43 (84-3C1, G19-1, and G10-2) both by flow cytometry (data not shown) and by APAAP (fig 11). Control cells transfected with vector alone were unlabelled.

Discussion
Although antibody MT1 has been used by many laboratories to stain T cells in paraffin wax sections, our report represents the first attempt to define its target molecule in human tissues. The data presented in this paper indicate that MT1 and also antibodies DF-T1 and L60 (Leu-22) all recognise a well defined molecule, the CD43 antigen, also known as sialophorin. The assignment of these antibodies to the CD43 group rests on data obtained by independent techniques—that is, biochemical analysis; reactivity on tissue sections, cell smears and cell suspensions; and staining of cells transfected with the cloned CD43 gene.

Biochemical analysis by Western blotting showed that the antibodies react with molecules of identical weight, although there was clear variation between different sources of the antigen (range 95–160 kilodaltons). This heterogeneity should be borne in mind when comparing the biochemical data obtained in the present paper with those of previous studies. The diffuse appearance of the bands in polyacrylamide gels is consistent with the high degree of glycosylation of CD43. This may be relevant to the suitability of these antibodies for use on routinely processed histological tissue sections, because other carbohydrate rich glycoproteins—CD15—for example, are known
to be resistant to formalin fixation.

Equivalent results were obtained with MT1, DF-T1, L60 (Leu-22) and the three anti-CD43 antibodies when they were compared on normal tissue sections. The patterns of reactivity obtained in tissue sections with myeloid cells, T cells, and some B cell tumours is consistent with the limited data obtained by flow cytometry in the Third Workshop. Double staining experiments by flow cytometry showed that CD43 was also found on some non-malignant B cells, usually at lower levels than T cells. The demonstration of CD43 antigen on B cells at levels below the threshold of standard immunohistological staining of tissue sections may be relevant to the finding that some cases of B cell neoplasia are positive for the antigen. Similarly, the existence of a few normal T cells which lack the CD43 antigen may account for T cell lymphomas with this phenotype.

The view that the six antibodies all detect the same molecule was independently corroborated by showing that the COS-7 monkey kidney cell line, which had been induced to express the CD43 antigen by transfection of the CD43 gene, was recognised by all six antibodies.

Antibodies MT1, DF-T1, and L60 (Leu-22) were also compared for their reactivity with previously phenotyped tumours. The antibodies were broadly equivalent but some discrepancies in the staining patterns were found. The differences were most evident when staining B cell neoplasms on which the antigen, when present, is often only weakly expressed. Reports of the rate at which MT1 reacts with B cell tumours in paraffin wax sections show considerable differences, ranging from 0–49% (table 4), and variability in MT1 staining caused by differences in fixation time has been noted previously. These results suggest that technical variables, such as fixation, enzymatic digestion, and staining, or differences in antibody avidity may influence the threshold for positive staining in paraffin wax sections, particularly when the antigen is present at low concentrations. It is of relevance that no differences between the reactions of the antibodies MT1, DF-T1, and L60 (Leu-22) were seen on CLL blood smears (in which there was less possibility of fixation and processing artefacts). Thus even when it is clear from biochemical studies that antibodies recognise the same molecule, differences in the staining reactions in sections from the same tumour do occur.

The observation that the antigen recognised by the six antibodies is found on some B cell tumours is reminiscent of CD5 expression on B cell CLL and some B cell lymphomas. The mechanism of expression on B CLL cells, however, is likely to be different for CD5 and CD43 because cases of CLL were encountered in which either one of these antigens was found in the absence of the other.

In conclusion, the antibody MT1, widely used for detecting T cells in paraffin wax sections, is not a unique reagent but belongs to the CD43 cluster first described in 1986. DF-T1 and L60 (Leu-22) also recognise the same molecule, and the three antibodies give broadly equivalent immunostaining on routinely processed tissue sections. It is clear that CD43 antigen is expressed on a proportion of B cell neoplasms, so that staining for this molecule, when phenotyping lymphoid proliferations, should always be accompanied by staining for other independent T cell markers such as anti-CD3 and UCHL1. The findings of our paper should help to prevent pathologists inadvertently staining with two anti-CD43 antibodies in the belief that they are detecting different T associated antigens.

Anti-CD43 antibodies may also be of value in showing that a T cell proliferation is neoplastic, because of the non-reactivity of the T cells, as has been shown with antibody L60 (Leu-22). The same study also showed that the expression of CD43 on B cell proliferations correlated with malignancy.

Finally, the reactivity with myeloid cells may be of practical value in providing additional evidence that cells are of this lineage. An example of this application is to be found in the report by Facchetti et al, that “plasmacytoid T cells” react with the anti-CD43 antibody MT1, but not with other anti-T cell reagents, providing evidence for a myeloid rather than a T cell origin.

KCG is a Wellcome Senior Research Fellow in clinical science. This work was supported by the Leukaemia Research Fund.

References

7 Cobbold S, Hale G, Waldmann H. Non-lineage, LFA-1, family,
15 Pharmacia Laboratory Separation Division. Specific monoclonal antibody purification techniques. 1986;May:1–3.

Requests for reprints to: Dr WP Stross, Nuffield Department of Pathology, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, England.
Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen.

W P Stross, R A Warnke, D J Flavell, S U Flavell, D Simmons, K C Gatter and D Y Mason

doi: 10.1136/jcp.42.9.953

Updated information and services can be found at:

http://jcp.bmj.com/content/42/9/953

*These include:*

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:

http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:

http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:

http://group.bmj.com/subscribe/